Beatriz Ferreira de Carvalho Patricio

Dr. Beatriz Ferreira de Carvalho Patricio

Departamento de Ciências Fisiológicas, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in ACS Omega
Verified
Journal Article
Open access
JVJoão Vitor Vicente-Da-Silva
João Vitor Vicente-Da-Silva
JPJuliana Oliveira da Silva Lopes Pereira
Juliana Oliveira da Silva Lopes Pereira
FCFlávia Carmo
Flávia Carmo
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
The skin plays a crucial role in the body's homeostasis through its thermoregulation functions, metabolic activity, and, mainly, its barrier function. Once this system has its homeostasis disturbed, through the promotion of tissue discontinuity, an injury happens and a restoration process starts. Different products can be used to promote, accelerate, or stimulate the healing process, such as hydrogels, emulsions, and ointments (main conventional formulations). Despite the historical use and wide market and consumer acceptance, new systems emerged for wound management with the main challenge to overcome conventional form limitations, in which nanosystems are found, mainly nanobased emulsion forms (nano- and microemulsions, NE and ME). Here, we discuss the skin function and wound healing process, highlighting the cellular and molecular processes, the different wound classifications, and factors that affect physiological healing. We also investigated the recent patents (2012-2023) filed at the United States Patent and Trademark Office, where we found few patents for conventional forms (hydrogels = 5; emulsions = 4; ointments = 6) but a larger number of patents for nanobased emulsions filed in this time (NE = 638; ME = 4,072). Furthermore, we address the use of nanobased emulsions (NE and ME) and their particularities, differences, and application in wound treatment. This work also discusses the challenges, bottlenecks, and regulatory framework for nanosystems, industrial, academic, and government interest in nanotechnology, and future perspectives about this key factor for the nanosystems market and consumer acceptance.

16 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Magno Maciel-MagalhãesMagno Maciel-Magalhães
Magno Maciel-Magalhães
RMRenata Jurema Medeiros
Renata Jurema Medeiros
NGNayara Cecilia Guedes
Nayara Cecilia Guedes
TBThais Morais de Brito
Thais Morais de Brito
GSGabriele Fátima de Souza
Gabriele Fátima de Souza
IDIsabella Fernandes Delgado
Isabella Fernandes Delgado
Background: Amphotericin B (AmB) is a commonly utilized antifungal agent, which is also recommended for the treatment of certain neglected tropical diseases, including leishmaniasis. However, its clinical application is constrained because of its poor oral bioavailability and adverse effects, prompting the investigation of alternative drug delivery systems. Polymeric nanoparticles (PNPs) have gained attention as a potential drug delivery vehicle, providing advantages such as sustained release and enhanced bioavailability, and could have potential as AmB carriers. However, concerns persist regarding nanomaterials’ toxicity, requiring more studies. Zebrafish (Danio rerio) embryos were used as a valuable model for toxicity testing, especially because of their genetic similarity to humans and standardized developmental assessments. Methods: In this study, we produced and characterized AmB loaded and non-loaded PNPs by nanoprecipitation, dynamic light scattering, transmission electron microscopy, atomic force microscopy and spectroscopy. Afterwards, we verified their toxicity through in vitro MTT assays in three cell lines (HEK293, HepG2, and J774 A1) and in vivo tests with zebrafish embryos. Results: In both trials, it was noted that nanoencapsulation of the drug led to increased toxicity when compared to non-encapsulated AmB, possibly indicating that they penetrated the embryo’s chorion. Nevertheless, it was demonstrated that the polymers used are safe and they are not the cause of toxicity, neither are the nanostructures per se. Conclusions: Therefore, it is believed that the objective of improving the bioavailability of AmB may have been achieved, and the observed toxicity was probably linked to AmB’s ability to destabilize cell membranes.

9 February 2024 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
JPJuliana Figueiredo Peixoto
Juliana Figueiredo Peixoto
LGLuiz Filipe Gonçalves-Oliveira
Luiz Filipe Gonçalves-Oliveira
FSFranklin Souza Silva
Franklin Souza Silva
LCLuzia Monteiro de Castro Côrtes
Luzia Monteiro de Castro Côrtes
LFLéa Cysne Finkelstein
Léa Cysne Finkelstein
Carlos Roberto AlvesCarlos Roberto Alves
Carlos Roberto Alves
Leishmaniasis is a disease caused by Leishmania spp., affecting millions of people around the world. For decades, its treatment has been based on pentavalent antimonials, which notoriously cause toxic side effects in patients. In this study, epoxy-alpha-lapachone incorporated into an oil-in-water-type microemulsion (ELAP-ME) and meglumine antimoniate (MA) were assayed in monotherapy and in combination (ELAP-ME/MA) in BALB/c mice infected with Leishmania (Leishmania) amazonensis. In general, there was a reduction in paw lesion size (up to 37% reduction) and decreases of parasite loads in the footpad (similar to 40%) and lymph nodes (similar to 31%) of animals treated with ELAP-ME/MA, when compared to the non-treated control groups. Analyses of serum biochemical parameters revealed that the ELAP-ME/MA showed lower renal and hepatic toxicity when compared to MA 2-doses/ week monotherapy. These findings indicate that the ELAP-ME/MA combination may be a promising approach for the treatment of cutaneous leishmaniasis.

10 May 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CSCarla Soares de Souza
Carla Soares de Souza
VLVictor Ropke da Cruz Lopes
Victor Ropke da Cruz Lopes
GBGabriel Barcellos
Gabriel Barcellos
FAFrancisco Alexandrino-Junior
Francisco Alexandrino-Junior
PNPatrícia Neves
Patrícia Neves
AFAlexandre Bezerra Conde Figueiredo
Alexandre Bezerra Conde Figueiredo
Fungal infections cause 1.7 million deaths annually, which can be attributed not only to fungus-specific factors, such as antifungal resistance and biofilm formation, but also to drug-related challenges. In this study, the potential of Amphotericin (AmB) loaded polymeric nanoparticles (AmB-NPs) combined with murine monoclonal antibodies (mAbs) (i.e., CC5 and DD11) was investigated as a strategy to overcome these challenges. To achieve this goal, AmB-NPs were prepared by nanoprecipitation using different polymers (polycaprolactone (PCL) and poly(D,L-lactide) (PLA)), followed by comprehensive characterization of their physicochemical properties and in vitro biological performance. The results revealed that AmB-loaded NPs exhibited no cytotoxicity toward mammalian cells (baby hamster kidney cells—BHK and human monocyte cells—THP-1). Conversely, both AmB-NPs demonstrated a cytotoxic effect against C. albicans, C. neoformans, and H. capsulatum throughout the entire evaluated range (from 10 µg/mL to 0.1 µg/mL), with a significant MIC of up to 0.031 µg/mL. Moreover, the combination of AmB-NPs with mAbs markedly intensified antifungal activity, resulting in a synergistic effect that was two to four times greater than that of AmB-NPs alone. These findings suggest that the combination of AmB-NPs with mAbs could be a promising new treatment for fungal infections that is potentially more effective and less toxic than current antifungal treatments.

1 June 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MSMichelle Sarcinelli
Michelle Sarcinelli
TSThalita Martins da Silva
Thalita Martins da Silva
ASAndressa Daniele Artico Silva
Andressa Daniele Artico Silva
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
FPFlávia Costa Mendes de Paiva
Flávia Costa Mendes de Paiva
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha

3 August 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Open access
TSThalita Martins da Silva
Thalita Martins da Silva
THThiago da Silva Honorio
Thiago da Silva Honorio
MCMarcelo Henrique da Cunha Chaves
Marcelo Henrique da Cunha Chaves
Marcelo Dutra DuqueMarcelo Dutra Duque
Marcelo Dutra Duque
LCLucio Cabral
Lucio Cabral
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha
This work aims to evaluate the ability of biorelevant dissolution media to simulate the bioavailability of efavirenz tablets, establish an in vitro–in vivo relationship (IVIVR) based on in vivo dat...